PMOS Together

PCOS HAS A NEW NAME! PMOS

Polyendocrine Metabolic Ovarian Syndrome (PMOS) is the new name for the condition previously known as Polycystic Ovary Syndrome (PCOS), which impacts 1 in 8, or more than 170 million women worldwide.

In our Pathways to Care for PCOS-PMOS in Alberta, assessing cardiometabolic risk at diagnosis is key to better care for those with PMOS (see below).

The new name, Polyendocrine Metabolic Ovarian Syndrome (PMOS), has just been published in The Lancet and is being announced currently at the European Congress of Endocrinology Conference May 2026.

Here are some resources and videos for you to share with your networks – https://bit.ly/3V85nPJ. There are patient and health professionals resources that have been translated in English, Arabic, Persian, Mandarin, German, Spanish, Portuguese, French, German and other languages.

For more information: https://www.mchri.org.au/guidelines-resources/community/pcos-resources-2

PMOS PATHWAYS & GUIDELINES

PMOS Clinical Pathway

PMOS Patient Pathway Web Content

PMOS Patient Pathway Summary (which is linked to the clinical pathway): Your Journey with PMOS (alberta.ca)

PMOS Patient Pathway (Full): Your Journey with PMOS (alberta.ca)

International Evidence-based Guidelines for the assessment and management of PMOS

OUR MISSION

PMOS Together's mission is to improve our understanding of health outcomes and health care in women with and without PMOS in Canada. The focus is on cardiometabolic risk, diabetes and cardiovascular disease and improving health care in those with PMOS.

PMOS Together is a research program aimed at understanding the health status and improving the health and health care of women with PMOS. To do this we are trying to understand the health risks and long term health outcomes in women with PMOS. We have found that women with PMOS in Alberta are at 2 and 3 fold higher risk for developing diabetes and cardiovascular disease. We are establishing methods to detect early disease risk in women with PMOS. We are also undertaking clinical interventions to treat high-risk women with PMOS in the prevention of diabetes and cardiovascular disease.